 = Add Download to Briefcase
|
Presentations
Scientific
| Title |
Date |
Type |
Size |
|
| ASCO 2013: Phase Ib Study Combining Ibrutinib with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Patients with CD20-Positive B-Cell Non Hodgkin Lymphoma (NHL). Younes, Anas et al. |
Jun 2, 2013 |
|
1.0 MB
|
|
| ASCO 2013: Use of Tumor Genomic Profiling to Reveal Mechanisms of Resistance to the BTK Inhibitor Ibrutinib in Chronic Lymphocytic Leukemia (CLL). Buggy, Joseph et al. |
Jun 2, 2013 |
|
435.5 KB
|
|
| ASCO 2013: Pharmacokinetics of Ibrutinib in Patients with Chronic Lymphocytic Leukemia. Sukbuntherng, Juthamas et al. |
Jun 2, 2013 |
|
150.1 KB
|
|
| ASCO 2013: Open Label Evaluation of ECG in Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Ibrutinib Monotherapy. Loury, David et al. |
Jun 2, 2013 |
|
231.8 KB
|
|
Pharmacyclics had 9 oral and 9 poster presentations at the 2012 American Society of Hematology (ASH) Annual Meeting providing an update on the broad development program of ibrutinib. These abstracts have been filed with the SEC and can be found at:
ASH 2012 Abstracts
Ramses Erdtmann
1 (408) 215-3325
rerdtmann@pcyc.com
Peter Rahmer
1 (646) 378-2973
prahmer@troutgroup.com
